Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
June 13 – 23: 2019 Men's Softball World Championship in Prague-Havlíčkův Brod Argentina defeated Japan, 3–2, to win their first Men's Softball World Championship title. Canada took third place. July 23 – 27: Europe/Africa Softball 2020 Olympic Qualifier in Utrecht Italy defeated Great Britain, 5–0, to book their team and compete at the 2020 Summer Olympics. July 26 – 30: 2019 Women's U12 Softball World Cup in Tainan (debut event) Chinese Taipei defeated Peru, 3–2, to win the inaugural Women's U12 Softball World Cup title. The Czech Republic took third place. Indonesia took fourth place. August 10 – 17: 2019 Women's U19 Softball World Cup in Irvine The United States defeated Japan, 4–3, to win their third consecutive and seventh overall Women's U19 Softball World Cup title. Canada took third place. August 25 – September 1: Americas Softball 2020 Olympic Qualifier in Surrey Champions: Mexico; Second: Canada; Third: Puerto Rico Note: Both Mexico and Canada have qualified to compete at the 2020 Summer Olympics. September 24 –28: Asia/Oceania Softball 2020 Olympic Qualifier in Shanghai Champions: Australia; Second: Chinese Taipei; Third: China Note: Australia has qualified to compete at the 2020 Summer Olympics.
In 1957, Chien-Shiung Wu et al. discovered that β-decay violated parity, implying nature (the weak force) sees handedness. In the Wu experiment, researchers aligned 60Co nuclei by cooling the source to low temperatures in a magnetic field. Wu's observation was that more β-rays were emitted in the opposite direction to the nuclear spin. This asymmetry violates parity conservation.
Thomas's body was brought back to Wales for burial in the village churchyard at Laugharne. Thomas's funeral, which Brinnin did not attend, took place at St Martin's Church in Laugharne on 24 November. Six friends from the village carried Thomas's coffin. Caitlin, without her customary hat, walked behind the coffin with his childhood friend Daniel Jones at her arm and her mother by her side. The procession to the church was filmed and the wake took place at Brown's Hotel. Thomas's fellow poet and long-time friend Vernon Watkins wrote The Times obituary. Though Thomas died intestate, with assets worth £100, substantial royalties would accrue from sales of his work, with half the proceeds allocated to Caitlin and half to the three children. A trust was established to administer the estate and protect the copyright of Thomas's work. Trustees included Daniel Jones, Wynford Vaughan Thomas and, in an unlikely development given his low opinion of Thomas, Kingsley Amis, who was appointed at the behest of the Thomas family solicitor and administrator of the trust, Stuart Thomas. After Caitlin, troubled by painful memories, left Laugharne to live in Italy, the Thomas family home, the Boathouse, became the home of her mother-in-law, Florence, for the last five years of her life. It was subsequently purchased by the trust from Margaret Taylor on behalf of Caitlin who sold it on to an educational charity before it was eventually acquired by Carmarthenshire County Council and opened to the public as a tourist attraction.
Sources: en.wikipedia.org
The 2026 FIFA World Cup was the 23rd FIFA World Cup, the quadrennial international men's soccer championship contested by the national teams of the member associations of FIFA. The tournament began on June 11, 2026, and concluded on July 19 with Spain winning the championship for the second time. It was jointly hosted by 16 cities—11 in the United States, 3 in Mexico, and 2 in Canada. The tournament was the first FIFA World Cup to be hosted by three countries and the first to include 48 teams, an expansion from the previous 32-team format. The 2026 tournament was the second World Cup to be hosted by multiple nations, after the 2002 edition. Mexico became the first country to host the World Cup three times, having hosted the 1970 and 1986 tournaments. The United States previously hosted the World Cup in 1994, while it was Canada's first time hosting the tournament. The event returned to its traditional June–July schedule after the 2022 World Cup in Qatar, which was uniquely held in November and December to avoid Qatar's extreme summer heat. Canada, Mexico, and the United States qualified automatically as hosts, while Cape Verde, Curaçao, Jordan, and Uzbekistan made their World Cup debuts. For the first time in the tournament's history, the top four teams from the FIFA Men's World Ranking at the time of the contest (Argentina, Spain, France, and England) advanced to the semifinals. Spain won the final against defending champion Argentina 1–0 after extra time, winning its second title and first since 2010.
This finding revealed to Schoenheimer that cholesterol was an active metabolite. Schoenheimer and his associates also investigated ergo-sterol, and its behaviour within the bodies of rats, mice, and rabbits. The findings of this study revealed that egro-sterol was not absorbable. This research shaped Schoenheimer's scientific career and research path.
=== Consumption === Global consumption of caffeine has been estimated at 120,000 tonnes per year, making it the world's most popular psychoactive substance. The consumption of caffeine has remained stable between 1997 and 2015. Coffee, tea and soft drinks are the most common caffeine sources, with energy drinks contributing little to the total caffeine intake across all age groups.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.